Novartis Institute of Medical Science
COX-2 inhibitors may be promising in treating bone cancer pain
Published in Surgery Litigation and Law Weekly, March 26th, 2004
"Chronic pain resulting from metastatic bone cancer remains poorly understood and resistant to treatment. Here we have examined the effect of the novel COX-2 enzyme inhibitor lumiracoxib in a model of bone cancer pain in the rat. Lumiracoxib was administered orally twice daily from day 10 to day 20 after injection of MRMT-1 tumor cells into one tibia," scientists in England report.
"Mechanical hyperalgesia, measured as the reduction in weight-bearing of the ipsilateral limb, and the development of static...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Surgery Litigation and Law Weekly
More Articles from Surgery Litigation and Law Weekly
- HydroCision, Inc.
Additional U.S. patent issued for fluidjet technology - LifeCell Corp.
Allograft-tissue company reports increased revenues - Royal Orthopedic Hospital, Birmingham
Adolescent survival rates for bone cancer have not improved for 20 years - Walter Reed Army Medical Center
Acute Wernicke's encephalopathy occurs after bariatric surgery - The National Heart and Lung Inst., London
Off-pump myocardial revascularization reduces stroke in elderly patients - Adelaide & Meath Hospital, Dublin
MRI identifies changes in pelvic muscle morphology in incontinent patients - More from this issue of Surgery Litigation and Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
